Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06492941 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer

StatusNot Yet Recruiting
PhasePhase 3
Started2024-08-12
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 9, 2024 (before its estimated April 14, 2026 completion). Its status may not reflect the trial's current state.
This study is a randomized, double-blind, multicenter, phase Ⅲ clinical study to compare the clinical efficacy and safety of Docetaxel for Injection (Albumin Bound) in combination with best supportive care versus placebo in combination with best supportive care in participants with pancreatic cancer who have received gemcitabine-containing and fluorouracil-containing regimens.
Trial Details
NCT Number NCT06492941
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Advanced Pancreatic Cancer
Enrollment 142 participants
Start Date 2024-08-12
Primary Completion 2026-04-14 (estimated)
Study Completion 2026-11-21 (estimated)
Updated on ClinicalTrials.gov 2024-07-09